Recent Updates
Recently added Catalysts

Recentin

Phase 1

Cancer | Small molecule | Oncology |AstraZeneca PLC|Last Updated: Jul 1, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment35

FDA Designations

No designations recorded

Clinical trial landscape

Recentin · 1 trial · 1 indication

Phase 1 1
NCT00748891DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)Cancer
COMPLETED35 Analytics
PHASE1COMPLETED
DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)
Cancer
NCT0074889135
Unlock trial analytics

Study Endpoints

Primary Endpoints

Percentage change in DCE-MRI and DCE-CT vascular parameters. Comparison between vascular parameters of each imaging modality and between modalities.
DCE-MRI and DCE-CT scans taken at Baseline, Day 7 and Day 28. Comparison between modalities from scans taken on Days -8 and Day-1.
Baseline measurements for DCE-MRI-iAUC60(mMol/sec),Ktrans(min-1),ve,vp,kep(min-1,Enhancing Fraction% DCE-CT-Permeability Surface Product(ml/min/100g),Perfusion(ml/min/100g),Mean Transit Time(sec),Blood Volume (ml/100g),Positive Enhancement Integral(Hus).
DCE-MRI and DCE-CT scans taken at Day -8, Day -1, Day 7 and Day 28

Secondary Endpoints

Objective tumour response (RECIST )Progression free survival
RECIST scans within 4 weeks prior to first dose then 8 weekly up to 24 weeks, then 12 weekly thereafter
Baseline and on treatment time-point measurements for iAUC60 (mMol/sec) and Positive Enhancement Integral (Hus)
DCE-MRI and DCE-CT scans taken at Day -8, Day -1, Day 7 and Day 28
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP

Treatment Arms

ArmTypeDescription
1EXPERIMENTALOpen label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression

Interventions

NameTypeDescription
Recentin (Cediranib)DRUG30mg once daily, oral dose
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Histologically confirmed metastatic tumour which is refractory to standard therapies * At least one lesion size ≥3cm on in longest diameter suitable for repeat assessment by DCE-CT and DCE-MRI * Patients must be able to undergo DCE-CT and DCE-MRI scanning procedures * Life exp...

Countries:United Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Cancer 5 trials

CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520/ GEH200521- Part A
Zimmer Biomet Holdings, Inc.ZBH1 - Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence

Frequently asked questions about Recentin

What is Recentin?

Recentin is an investigational small molecule being developed by AstraZeneca PLC for the treatment of cancer. It is currently in Phase 1 clinical development. Recentin is being studied in oncology, and it is not yet approved for any use.

What is Recentin used for?

Recentin is being studied for use in cancer. It is an investigational oncology drug in Phase 1 clinical development. Recentin is not yet approved for any indication, and its safety and efficacy have not been established.

Who makes Recentin?

Recentin is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate Recentin as a potential cancer treatment.

What phase is Recentin in?

Recentin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Recentin is being studied for the treatment of cancer, and its development is still in the early stages.

What clinical trials is Recentin in?

Recentin has been studied in one completed Phase 1 clinical trial, NCT00748891, titled 'DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)'. This trial enrolled 35 patients with cancer in the United Kingdom and was not randomized or double-blinded.